<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299646</url>
  </required_header>
  <id_info>
    <org_study_id>GETUG-StORM-01</org_study_id>
    <nct_id>NCT04299646</nct_id>
  </id_info>
  <brief_title>Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases</brief_title>
  <acronym>GETUG-StORM-01</acronym>
  <official_title>A Randomized Phase II Study Assessing Stereotactic Radiotherapy in Therapeutic Strategy of Oligoprogressive Renal Cell Carcinoma Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GETUG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Every year, 12500 primary renal cell carcinoma (RCC) are diagnosed in France. Metastases
      occur in half of RCC patients.

      Management of metastatic RCC is based on systemic treatments (targeted
      therapies/immunotherapy). However, resistance to systemic treatment is frequent. In case of
      progression, usual therapeutic attitude is initiating another systemic therapy.

      Because of the emergence of resistant tumor clonal cells, some patients progress only on few
      sites while the rest of tumor burden is controlled. In this setting named oligoprogressive
      disease [isolated progression of &lt;3-5 metastase(s)], ablative treatments of these evolving
      metastatic sites could allow a disease control and a reduced risk of new metastases
      occurrence by tumor-cell reembolization. Such strategy is challenging to prolong ongoing
      systemic treatment and delay further lines.

      Although RCC was considered radioresistant and radiotherapy with conventional fractionation
      was mainly used for palliation of symptoms, stereotactic radiotherapy (SRT), by delivering
      high dose in one or few fractions, allows local control for about 90% of RCC metastases
      through various radiobiological pathways. Furthermore, some data suggest that high-dose focal
      irradiation of RCC could induce a systemic antitumor response mediated by immunologic
      effectors(1). This phenomenon (&quot;abscopal effect&quot;) could be enhanced in patients under
      immunotherapy, including anti-PD1.

      Several retrospective studies and one non-randomized phase-II study highly suggest the
      interest of SRT as focal ablative treatment in RCC oligometastases with excellent local
      control rates and low toxicity(2,3).

      Furthermore, the multicentric retrospective study the sponsor recently conducted within the
      GETUG group among 101 metastatic RCC patients with oligoprogression under systemic therapy
      highlighted that SRT on progressive sites provided a median of 8.6-month progression-free
      survival and allowed to continue current systemic line for 10.5 months.

      However, to date, there are no prospective data assessing the interest of SRT for management
      of oligoprogressive metastatic RCC.

      The sponsor aim to prospectively evaluate the interest of SRT as a therapeutic strategy for
      local control of oligoprogressive metastatic RCC under ongoing systemic treatment, and
      consequently delay subsequent systemic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized 2:1 phase II trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>6 months post-randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>Until 1 month after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local control rate</measure>
    <time_frame>3, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall control rate</measure>
    <time_frame>3, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">114</enrollment>
  <condition>Metastatic Renal Cell Carcinoma</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Systemic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Steretactic radiotherapy</intervention_name>
    <description>Steretactic radiotherapy</description>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pursuit of ongoing systemic treatment</intervention_name>
    <description>Pursuit of ongoing systemic treatment</description>
    <arm_group_label>Steretactic radiotherapy plus systemic treatment</arm_group_label>
    <arm_group_label>Systemic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clear cell renal cancer histologically proved (association with other histologic
             component are permitted)

          -  Patients of good or intermediate prognostic, according to Heng criteria

          -  Extracerebral metastatic disease documented with imagery

          -  Patients treated in first or second line systemic therapy

          -  Systemic treatment may be targeted therapies (tyrosine kinase inhibitors or mammalian
             target of rapamycin inhibitors) and/or immunotherapy according to French applicable
             standards; patients treated in a clinical trial are also eligible if allowed by trial
             sponsor

          -  Oligoprogressive disease documented with imagery, defined as the emergence or
             progression of 1 to 3 metastases and progression localized in up to 2 organs

          -  Oligoprogressive disease confirmed with 2 CT scans performed 2 months apart

          -  At least one measurable progressing metastasis according to R.E.C.I.S.T. criteria v1.1

          -  All oligoprogressive target lesions measuring ≤ 4 cm

          -  Good general condition (WHO performance status ≤ 2)

          -  All progressive lesions have to be accessible to SRT, performed concurrently or
             sequentially

          -  No contraindication to systemic therapy and stereotactic radiation therapy

          -  Patients aged 18 years or older

          -  Signed informed consent form

          -  Patients affiliated to the social security system

        Exclusion Criteria:

          -  More than 3 progressive metastases

          -  Non measurable disease according R.E.C.I.S.T. criteria

          -  Patients who received 3 or more lines of systemic therapy

          -  Inability to treat all progressive metastatic sites with SRT

          -  Previous radiation therapy performed in ≥ 1 target lesion

          -  At least 1 oligoprogressive target lesion measuring &gt; 4 cm

          -  Presence of brain metastases

          -  Presence of ultra-central pulmonary metastasis

          -  Progressing metastasis in a long bone

          -  At least 1 progressive metastasis requiring surgical treatment

          -  Current or past history of second neoplasm diagnosed within the last 5 years

          -  Pregnancy or breast feeding or inadequate contraceptive measures

          -  Patients who cannot be adequately followed up

          -  Patient deprived of freedom or under guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Emmanuel MEYER, MD</last_name>
    <phone>+ 332 31 45 50 20</phone>
    <email>e.meyer@mail.baclesse.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Michel GRELLARD</last_name>
    <phone>+33 2 31 45 50 02</phone>
    <email>jm.grellard@baclesse.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinique Claude Bernard</name>
      <address>
        <city>Albi</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurent VOTRON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Laurent VOTRON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Claude ALZIEU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre AUBERDIAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yan BERGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérémy COLLIAUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jérémy COLLIAUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie MESGOUEZ-NEBOUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hadji HAMIDOU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thibaut LIZEE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pauline GILLON, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pauline GILLON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radiothérapie Bordeaux Nord Aquitaine</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sigolène GALLAND-GIRODET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>François GUICHARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bénédicte HENRIQUES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MEYER, MD</last_name>
      <phone>+33 2 31 45 50 20</phone>
      <email>e.meyer@mail.baclesse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Jean-Michel jm.grellard@baclesse.unicancer.fr</last_name>
      <phone>+33 2 31 45 50 02</phone>
      <email>jm.grellard@baclesse.unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Emmanuel MEYER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence JOLY, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Emmanuel BRACHET, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elodie COQUAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Genevieve LOOS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Genevieve LOOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hakim MAHAMMEDI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jessica MIROIR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yacid BELKACEMI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yacid BELKACEMI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gabriele CORAGGIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de cancérologie de Bourgogne (Dijon, Auxerre, Chalon sur Saône)</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis LEPINOY, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexis LEPINOY, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Benjamin SCHIPMAN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Véronique LORGIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas LESCUT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Naji SALEM, MD</last_name>
    </contact>
    <investigator>
      <last_name>Naji SALEM, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gwenaëlle GRAVIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cécile VICIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathilde GUERIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Slimane DERMECHE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Géraldine PIGNOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochen WALZ, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xavier MURACCIOLE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Xavier MURACCIOLE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric LECHEVALLIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles KARSENTY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Laurent DEVILLE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>veronique DELAPORTE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ICM</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David AZRIA, PhD</last_name>
    </contact>
    <investigator>
      <last_name>David AZRIA, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie CHARISSOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diego TOSI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen LLACER-MOSCARDO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie VIALA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anais STEFANI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anais STEFANI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne-Sophie BAUMANN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François PY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephane SUPIOT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephane SUPIOT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valentine GUIMAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vincent LIBOIS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel RIO, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Haute Energie</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>René Jean BENSADOUN, PhD</last_name>
    </contact>
    <investigator>
      <last_name>René Jean BENSADOUN, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samar Line KRHLI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samar Line KRHLI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles CREHANGE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathieu MINSAT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas FREDERIC MOREAU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de la Loire Lucien Neuwirth</name>
      <address>
        <city>Saint-Étienne</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas MAGNE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas MAGNE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien LANGRAND-ESCURE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexis VALLARD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jane-Chloé TRONE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grégoire PIGNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUCT</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pierre GRAFF-CAILLEAUD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jonathan KHALIFA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

